Interleukin 1β and tumour necrosis factor α secreting cells are increased in the peripheral blood of patients with primary Sjögren's syndrome

Annals of the Rheumatic Diseases

Volumn 62, Issue 4, 2003, Pages 359-362

  Willeke, P ^a   Schotte, H ^a   Schluter B ^a   Erren, M ^a   Becker, H ^a   Dyong, A ^a   Mickholz, E ^a   Domschke, W ^a   Gaubitz, M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 1BETA; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1;

ADULT; ANTIBODY TITER; ARTICLE; CELL COUNT; CELL ISOLATION; CELL SECRETION; CELL SWELLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SJOEGREN SYNDROME; AGED; BLOOD; CELL CULTURE; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; AGED; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037378848     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.4.359     Document Type: Article

References (17)

1. Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in Sjögren's syndrome salivary glands. Lab Invest 1997;77:269-80.
2. Garcic-Corrosco M, Font J, Filella X, Cervera R, Ramos-Casals M, Siso A, et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001;19:411-15.
3. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152:5532-9.
4. Tishler M, Yaron I, Shirazi I, Yossipov Y, Yaron M. Increased salivary interleukin-6 levels in patients with primary Sjögren's syndrome. Rheumatol Int 1999;18:125-7.
5. Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. Ophthalmology 1998;105:2327-9.
6. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92.
7. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
8. Zabel P, Linnemann K, Schlaak M. Circadian rhythm in cytokines. Immun Infekt 1993;21 (suppl 1):38-40.
9. Willeke P, Schotte H, Erren M, Schluther B, Mickholz E, Domschke W, et al. Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in patients with active systenic lupus erythematosus. Cell Mol Biol (Noisy-le-grand) 2002;48:323-9.
10. Tornwald J, Fox H, Edwards C, Fox RI. Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type 1 receptor (PEG sTNF-R1) prevents development of Sjögren's syndrome and diabetes in the NOD mouse model [abstract]. Arthritis Rheum 2000;42[suppl 9):403.
11. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infriximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
12. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147-56.
13. Yamakawa M, Weinstein R, Tsuji T, McBride J, Wong DT, Login GR. Age-related alterations in IL-1beta, TNF-alpha, and IL-6 concentrations in parotid acinar cells from BALB/c and non-obese diabetic mice. J Histochem Cytochem 2000;48:1033-42.
14. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessmen of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized pracebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
15. Warnatz H, Ruschen S, Lemm G. Interreukin-1 in the pathogenesis of chronic polyarthritis. Med Klin 1990;85:302-7.
16. Hagiwara E, Pando J Ishigatsuba Y Klinman DM. Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjögren's syndrome. J Rheumatol 1998;25:89-93.
17. Halse A, Tengner P Wahren-Herlenius M, Haga H, Jonsson R. Increased frequency of cells secreting inrerreukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999;49:533-8.